21 Mar
Innovative Cancer Therapy for Tomorrow: New Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia
Presenter: Hagop Kantarjian, MD, Chairman and Professor, Leukemia Department, University of Texas MD Anderson Cancer Center, Houston, Texas Nearly 70% of patients with early-chronic-phase CML who receive imatinib mesylate (Gleevec, Novartis) achieve a complete cytogenetic response. After a median follow-up of five years, the annual rate of resistance with progression was 4%, and the annual [...]